Finance

Whole Biome, an evidence-based microbiome company, today announced that it has secured $35 million in Series B financing. The round was led by existing investor Sequoia Capital with repeat participation from True Ventures, Khosla Ventures, […]

Crown Laboratories, Inc. (“Crown”), a leading, fully integrated skin care company, announced it has acquired Xycrobe Therapeutics, Inc. (“Xycrobe”). Xycrobe’s technology focuses on utilizing the ubiquitous nature of skin microbes by turning them into vehicles […]

Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic Biotic™ medicine, SYNB1891, […]

MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated […]

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, has raised an additional $18.5 million as an extension of its Series C […]

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the […]

Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]

Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]

Kintai is pioneering precision therapeutics based on enteric signaling networks in the human body Flagship Pioneering, a unique life science innovation enterprise, today unveiled Kintai Therapeutics and named Paul-Peter Tak, M.D., Ph.D., as president, chief […]

Danish bioscience company, Chr. Hansen, joins forces with Lonza AG to pioneer the emerging market for live biotherapeutic products Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading pharma contract […]